U.S. IT Stock News

Recent share performance and business scale Loma Negra Compañía Industrial Argentina Sociedad Anónima (LOMA) has seen its stock decline 14.7% year to date, while the past 3 months show a gain of 4.4% and the month is broadly flat. For context on the underlying business, the company reports revenue of roughly $850,476.19 and net income of about $36,113.48. Its operations span cement, concrete, aggregates, railway services and other related activities in Argentina. See our latest analysis for...

Why Hotel101 Global Holdings Stock Is Drawing Attention Now Hotel101 Global Holdings (NasdaqCM:HBNB) has been drawing attention after a period of weak share performance, with the stock down 8% over the past month and 33% over the past 3 months. For investors, the recent slide sits alongside a market value of about US$1.32b, revenue of US$75.87 million from property development, and a net loss of US$26.71 million. This combination is prompting a closer look at the business model. See our...

Yesway (YSWY) is drawing attention after its recent share performance, with the stock down about 15% over the past month following a modest single-day and past-week decline. See our latest analysis for Yesway. That 14.6% decline in the 30 day share price return, alongside a small year to date share price gain of 3.7% with the stock now at US$22.01, suggests recent momentum has cooled after a firmer start to the year. If you are looking beyond Yesway and want ideas with a similar risk on...

Celcuity (CELC) has moved into focus after reporting Phase 3 VIKTORIA-1 data for gedatolisib and securing FDA Priority Review, alongside a newly priced US$500 million convertible senior notes offering due 2032. See our latest analysis for Celcuity. Despite the positive Phase 3 VIKTORIA-1 data and FDA Priority Review, Celcuity’s share price has pulled back sharply in recent weeks, with a 30 day share price return of down 33.3%, even as the 1 year total shareholder return is very large and...

Digital Turbine (APPS) has moved back into growth mode, with 15% year-over-year revenue expansion, sharply reduced net losses, and fresh guidance for fiscal 2027. These developments are supported by the launch of its new Launchpad platform. See our latest analysis for Digital Turbine. Those product launches and improving results have gone hand in hand with a sharp re-rating in the stock, with a 131.44% 1 month share price return and 82.97% 1 year total shareholder return. However, the 5 year...

Evertec recently disclosed that it had detected potential unauthorized access to customer data via a third-party support platform used by financial institution clients, primarily in Puerto Rico, and has begun investigation and containment efforts without reporting any service interruptions. This incident highlights how operational reliance on external technology vendors can introduce data security vulnerabilities that matter for both customers and investors. We’ll now examine how this...

Jackson Financial Inc. recently completed a US$748.73 million fixed-rate senior unsecured notes offering, issuing 6.150% callable notes due January 15, 2037 at a slight discount to par. At the same time, Jackson’s launch of new registered index-linked annuities with added index options and funding flexibility highlights an effort to broaden and modernize its retirement income lineup. Next, we’ll examine how this combination of new RILA features and fresh long-term funding could shape Jackson...

Bentley Systems recently reported a strong start to 2026, with revenue up 14.5% year over year and continued growth in subscription and annual recurring revenue, while reshaping its balance sheet by repaying convertible notes and securing a new US$550 million term loan. The combination of accelerating AI-enabled engineering workflows and fresh financing capacity for potential acquisitions and capital allocation is reshaping how Bentley Systems is positioned for future corporate decisions and...

Encompass Health recently completed a US$500,000,000 private offering of 5.875% senior notes due 2034, primarily to refinance existing 4.500% 2028 notes, repay revolving credit facility borrowings, and cover related fees, while also opening plans for a new 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia to replace a closed 19-bed unit. This combination of balance sheet reshaping through longer-dated, higher-coupon unsecured debt and continued investment in specialized...

In its latest quarterly update, Fidelity National Financial reported US$3.23 billion in revenue, an 18.2% year-on-year increase that nonetheless fell short of analyst expectations for both sales and earnings per share. This combination of growth and an earnings miss highlighted a gap between the company’s recent operating performance and the projections embedded in prior analyst models. Now we will consider how this revenue and EPS shortfall against expectations affects Fidelity National...

Recent commentary around ManpowerGroup (MAN) centers on a mixed picture, with its employment survey pointing to resilient hiring plans, while flat sales, declining earnings per share, and shrinking returns on capital keep investor sentiment cautious. See our latest analysis for ManpowerGroup. At a share price of US$32.43, ManpowerGroup has seen a 16.9% 90 day share price return and an 8.7% 30 day share price return, yet its 1 year total shareholder return is still down 16.5%. This suggests...

Warby Parker (NYSE:WRBY) has been added to the S&P SmallCap 600 index, a move that can influence its visibility with index funds and institutional investors. The company also announced a partnership with Google to develop AI-powered intelligent eyewear, bringing smart functionality to its consumer eyewear offering. Warby Parker operates across omnichannel retail and e-commerce, selling prescription glasses, sunglasses, contacts and related eye care services. The S&P SmallCap 600 addition...

NIO (NYSE:NIO) has been added to the U.S. Department of Defense list of Chinese military companies, introducing new geopolitical and regulatory questions for the business. The company has publicly pushed back on the designation and is addressing potential implications for its international operations and brand. At the same time, NIO reports early demand for its new ES9 flagship SUV, alongside a higher average transaction price for the brand. NIO is also adjusting its international approach,...

Over the last 7 days, the United States market has experienced a 2.7% drop, though it has risen by 23% over the past year, with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying undervalued stocks can present opportunities for investors seeking to capitalize on potential growth and favorable market estimates.

Over the last 7 days, the United States market has dropped 2.7%, yet it has shown resilience with a 23% rise over the past year and expectations for earnings to grow by 17% annually in the coming years. In this context, growth companies with high insider ownership, such as ATRenew and two others we'll explore, can be particularly appealing as they often indicate strong internal confidence in their long-term potential.

Over the last 7 days, the United States market has dropped 2.7%, but it has risen by 23% in the past year, with earnings forecasted to grow by 17% annually. For investors willing to explore beyond well-known stocks, penny stocks—though a somewhat outdated term—still represent an intriguing investment area due to their affordability and potential for growth. This article highlights three penny stocks that stand out for their financial strength and resilience, offering compelling opportunities...

Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 17% annually. In such dynamic conditions, dividend stocks that offer consistent payouts and potential for capital appreciation can be an attractive option for investors seeking stability and income.

Apogee Therapeutics (APGE) stock is in focus after positive 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis, followed by a milestone-based, non-dilutive financing package of up to US$1.3b from Blackstone Life Sciences. See our latest analysis for Apogee Therapeutics. After a sharp rally tied to the Phase 2 APEX data and US$1.3b Blackstone financing, Apogee’s share price has eased 4.5% over the last day, although the 1-year total shareholder return of 106.85% points to strong...

In May 2026, Guardian Pharmacy Services, Inc. entered into an eighth amendment to its long-standing loan and security agreement, extending the revolving credit facility’s maturity to May 21, 2030, expanding potential borrowing capacity to US$80 million, and updating covenants to a consolidated net leverage ratio framework. This refinancing package gives Guardian more room to manage debt against cash and Adjusted EBITDA, which may influence how investors assess its balance sheet flexibility...

CPS Technologies (CPSH) has filed a follow-on equity offering to raise US$9.6 million by issuing 1,200,000 common shares at US$8 each in a registered direct deal, introducing fresh capital and potential dilution. See our latest analysis for CPS Technologies. The follow on offering comes after a sharp run, with a 30 day share price return of 95.21% and year to date share price return of 142.19%. The 1 year total shareholder return of 181.82% points to strong longer term momentum despite...

Tarsus Pharmaceuticals (TARS) has been drawing attention after recent trading swings, with the stock closing at US$59.64 while showing mixed returns over the past month and past 3 months, alongside a positive one year track record. See our latest analysis for Tarsus Pharmaceuticals. The share price has been under pressure in recent months, with a 90 day share price return down 18.32% and year to date share price return down 26.16%. At the same time, the 1 year total shareholder return sits at...

Lumentum Holdings recently raised its fourth-quarter guidance and reported very large year-over-year revenue growth, citing intense AI-driven demand for its cloud networking and optical components, while also executing a US$650.4 million private exchange of convertible notes for equity to reduce debt. At the same time, the company secured a multi-year US$2 billion agreement with Nvidia and is expanding manufacturing capacity, including an indium phosphide fab in North Carolina, highlighting...

Event context and recent stock performance Palvella Therapeutics (PVLA) has drawn fresh attention after recent trading saw the stock close at US$105.25. This move comes alongside a year-to-date gain of 5% and a 1-year total return near 3x. See our latest analysis for Palvella Therapeutics. Recent trading has been choppy, with the share price down 3.15% on the day, 6.52% over the past week and 25.94% over the past quarter. At the same time, the 1 year total shareholder return sits near 3x,...

Why Azenta (AZTA) is on investors’ radar today Azenta (AZTA) continues to draw attention after a mixed stretch of performance that includes a gain over the past month but weaker returns year to date and over the past year. With a market value of about US$1.0b and reported revenue of US$596.5m, the company sits in an interesting spot for investors comparing growth potential, profitability and valuation against other life sciences service providers. See our latest analysis for Azenta. At the...